- Home
- IMMX vs YSXT Comparison
IMMX vs YSXT Comparison
Compare IMMX & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- YSXT
- Stock Information
- Founded
- IMMX 2014
- YSXT 2011
- Country
- IMMX United States
- YSXT China
- Employees
- IMMX N/A
- YSXT N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- YSXT Automotive Aftermarket
- Sector
- IMMX Health Care
- YSXT Consumer Discretionary
- Exchange
- IMMX Nasdaq
- YSXT Nasdaq
- Market Cap
- IMMX 65.5M
- YSXT 58.6M
- IPO Year
- IMMX 2021
- YSXT 2024
- Fundamental
- Price
- IMMX $2.00
- YSXT $2.66
- Analyst Decision
- IMMX Strong Buy
- YSXT
- Analyst Count
- IMMX 1
- YSXT 0
- Target Price
- IMMX $8.00
- YSXT N/A
- AVG Volume (30 Days)
- IMMX 183.0K
- YSXT 876.8K
- Earning Date
- IMMX 11-11-2025
- YSXT 07-31-2025
- Dividend Yield
- IMMX N/A
- YSXT N/A
- EPS Growth
- IMMX N/A
- YSXT N/A
- EPS
- IMMX N/A
- YSXT 0.18
- Revenue
- IMMX N/A
- YSXT $71,452,736.00
- Revenue This Year
- IMMX N/A
- YSXT N/A
- Revenue Next Year
- IMMX N/A
- YSXT N/A
- P/E Ratio
- IMMX N/A
- YSXT $14.65
- Revenue Growth
- IMMX N/A
- YSXT 22.04
- 52 Week Low
- IMMX $1.26
- YSXT $1.68
- 52 Week High
- IMMX $3.20
- YSXT $9.96
- Technical
- Relative Strength Index (RSI)
- IMMX 48.92
- YSXT 51.40
- Support Level
- IMMX N/A
- YSXT N/A
- Resistance Level
- IMMX $2.34
- YSXT $2.80
- Average True Range (ATR)
- IMMX 0.15
- YSXT 0.36
- MACD
- IMMX -0.08
- YSXT 0.00
- Stochastic Oscillator
- IMMX 85.11
- YSXT 53.09
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.